SG11202009195WA - Heterobicyclic inhibitors of mat2a and methods of use for treating cancer - Google Patents
Heterobicyclic inhibitors of mat2a and methods of use for treating cancerInfo
- Publication number
- SG11202009195WA SG11202009195WA SG11202009195WA SG11202009195WA SG11202009195WA SG 11202009195W A SG11202009195W A SG 11202009195WA SG 11202009195W A SG11202009195W A SG 11202009195WA SG 11202009195W A SG11202009195W A SG 11202009195WA SG 11202009195W A SG11202009195W A SG 11202009195WA
- Authority
- SG
- Singapore
- Prior art keywords
- mat2a
- methods
- treating cancer
- heterobicyclic
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018081328 | 2018-03-30 | ||
| PCT/US2019/024645 WO2019191470A1 (en) | 2018-03-30 | 2019-03-28 | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202009195WA true SG11202009195WA (en) | 2020-10-29 |
Family
ID=67439309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202009195WA SG11202009195WA (en) | 2018-03-30 | 2019-03-28 | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11524960B2 (ja) |
| EP (1) | EP3774805B1 (ja) |
| JP (2) | JP7350005B2 (ja) |
| KR (1) | KR20200138769A (ja) |
| CN (1) | CN111936499B (ja) |
| AR (1) | AR115326A1 (ja) |
| AU (1) | AU2019243289B2 (ja) |
| BR (1) | BR112020020104A2 (ja) |
| CA (1) | CA3094476A1 (ja) |
| EA (1) | EA202092320A1 (ja) |
| IL (1) | IL277665B2 (ja) |
| MA (1) | MA52232A (ja) |
| MX (1) | MX2020010005A (ja) |
| PH (1) | PH12020551507A1 (ja) |
| PL (1) | PL3774805T3 (ja) |
| SG (1) | SG11202009195WA (ja) |
| TW (1) | TWI719437B (ja) |
| UA (1) | UA127059C2 (ja) |
| WO (1) | WO2019191470A1 (ja) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019395338A1 (en) | 2018-12-10 | 2021-07-29 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors |
| EP3902803B1 (en) * | 2018-12-27 | 2023-02-01 | Les Laboratoires Servier | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
| MA54609A (fr) * | 2018-12-27 | 2022-04-06 | Les Laboratoires Servier Sas | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer |
| CA3142340A1 (en) * | 2019-05-31 | 2020-12-03 | Les Laboratoires Servier | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
| US20230257359A1 (en) * | 2020-06-10 | 2023-08-17 | Ideaya Biosciences, Inc. | 4-arylquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| WO2021252681A1 (en) * | 2020-06-10 | 2021-12-16 | Ideaya Biosciences, Inc. | Quinolinone derivatives as methionine adenosyltransferase 2a inhibitors |
| EP4165035A1 (en) * | 2020-06-10 | 2023-04-19 | Ideaya Biosciences, Inc. | Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| US20230257377A1 (en) * | 2020-06-10 | 2023-08-17 | Ideaya Biosciences, Inc. | 2-aminoquinazolinone derivatives as methionine adenosyltransferase 2a inhibitors |
| WO2022052924A1 (zh) * | 2020-09-11 | 2022-03-17 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物的制备方法和用途 |
| WO2022053022A1 (zh) * | 2020-09-12 | 2022-03-17 | 赛诺哈勃药业（成都）有限公司 | 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 |
| CN115960099A (zh) * | 2020-09-24 | 2023-04-14 | 上海凌达生物医药有限公司 | 一类芳环或芳基杂环并吡啶酮类化合物、药物组合物及其应用 |
| CN116670144A (zh) | 2020-12-31 | 2023-08-29 | 南京再明医药有限公司 | 三环类化合物及用途 |
| WO2022206730A1 (zh) * | 2021-03-29 | 2022-10-06 | 武汉人福创新药物研发中心有限公司 | 嘧啶并吡嗪酮化合物及其用途 |
| CN115215862A (zh) * | 2021-04-19 | 2022-10-21 | 武汉人福创新药物研发中心有限公司 | 嘧啶酮化合物及其用途 |
| CN117412967A (zh) * | 2021-06-02 | 2024-01-16 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a抑制剂 |
| WO2023083210A1 (zh) * | 2021-11-09 | 2023-05-19 | 上海海雁医药科技有限公司 | 取代的萘啶酮衍生物、其药物组合物及应用 |
| CN114028572B (zh) * | 2021-11-30 | 2022-11-25 | 清华大学 | Mat2a抑制剂用于治疗哮喘的新应用 |
| WO2023116696A1 (zh) * | 2021-12-21 | 2023-06-29 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a的杂环抑制剂 |
| WO2023125737A1 (en) * | 2021-12-29 | 2023-07-06 | Silexon Ai Technology Co., Ltd. | Heterocyclic compounds and use thereof |
| WO2023143356A1 (zh) * | 2022-01-26 | 2023-08-03 | 勤浩医药（苏州）有限公司 | 用于治疗mtap缺失型癌症的甲硫氨酸腺苷转移酶2a抑制剂 |
| TW202342024A (zh) * | 2022-03-11 | 2023-11-01 | 大陸商賽諾哈勃藥業（成都）有限公司 | 甲硫胺酸腺苷轉移酶抑制劑、其藥物組合物及應用 |
| CN117430596A (zh) * | 2022-07-13 | 2024-01-23 | 上海海和药物研究开发股份有限公司 | 二并环类mat2a抑制剂及其用途 |
| KR20240051860A (ko) | 2022-10-13 | 2024-04-22 | 한미약품 주식회사 | 신규한 트리사이클 유도체 화합물 및 이의 용도 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999064400A1 (en) | 1998-06-12 | 1999-12-16 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF p38 |
| US6576420B1 (en) | 1998-06-23 | 2003-06-10 | Regents Of The University Of California | Method for early diagnosis of, and determination of prognosis in, cancer |
| WO2004014378A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
| TR201802464T4 (tr) * | 2009-10-29 | 2018-03-21 | Genosco | Ki̇naz i̇nhi̇bi̇törleri̇ |
| US20160115164A1 (en) * | 2014-10-22 | 2016-04-28 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) * | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| EP3481830B1 (en) * | 2016-07-05 | 2022-02-16 | The Broad Institute, Inc. | Bicyclic urea kinase inhibitors and uses thereof |
| CA3034705C (en) * | 2016-08-31 | 2021-08-03 | Agios Pharmaceuticals, Inc. | Inhibitors of cellular metabolic processes |
| WO2018039972A1 (en) * | 2016-08-31 | 2018-03-08 | Agios Pharmaceuticals, Inc. | Inhibitors of cellular metabolic processes |
-
2019
- 2019-03-28 BR BR112020020104-9A patent/BR112020020104A2/pt unknown
- 2019-03-28 EA EA202092320A patent/EA202092320A1/ru unknown
- 2019-03-28 EP EP19744896.2A patent/EP3774805B1/en active Active
- 2019-03-28 AU AU2019243289A patent/AU2019243289B2/en active Active
- 2019-03-28 MA MA052232A patent/MA52232A/fr unknown
- 2019-03-28 JP JP2020552849A patent/JP7350005B2/ja active Active
- 2019-03-28 MX MX2020010005A patent/MX2020010005A/es unknown
- 2019-03-28 SG SG11202009195WA patent/SG11202009195WA/en unknown
- 2019-03-28 US US17/040,614 patent/US11524960B2/en active Active
- 2019-03-28 KR KR1020207030741A patent/KR20200138769A/ko not_active Application Discontinuation
- 2019-03-28 PL PL19744896.2T patent/PL3774805T3/pl unknown
- 2019-03-28 CN CN201980023557.8A patent/CN111936499B/zh active Active
- 2019-03-28 CA CA3094476A patent/CA3094476A1/en active Pending
- 2019-03-28 WO PCT/US2019/024645 patent/WO2019191470A1/en unknown
- 2019-03-28 UA UAA202006905A patent/UA127059C2/uk unknown
- 2019-03-29 TW TW108111265A patent/TWI719437B/zh active
- 2019-03-29 AR ARP190100845A patent/AR115326A1/es unknown
-
2020
- 2020-09-18 PH PH12020551507A patent/PH12020551507A1/en unknown
- 2020-09-29 IL IL277665A patent/IL277665B2/en unknown
-
2023
- 2023-06-01 JP JP2023090963A patent/JP2023101762A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019243289B2 (en) | 2023-01-12 |
| PH12020551507A1 (en) | 2021-09-13 |
| AR115326A1 (es) | 2020-12-23 |
| WO2019191470A1 (en) | 2019-10-03 |
| CA3094476A1 (en) | 2019-10-03 |
| BR112020020104A2 (pt) | 2021-01-26 |
| UA127059C2 (uk) | 2023-03-29 |
| TWI719437B (zh) | 2021-02-21 |
| US11524960B2 (en) | 2022-12-13 |
| PL3774805T3 (pl) | 2024-05-06 |
| IL277665A (en) | 2020-11-30 |
| IL277665B2 (en) | 2023-06-01 |
| EP3774805A1 (en) | 2021-02-17 |
| WO2019191470A8 (en) | 2019-12-12 |
| JP2023101762A (ja) | 2023-07-21 |
| CN111936499B (zh) | 2023-09-19 |
| EP3774805B1 (en) | 2024-01-10 |
| JP7350005B2 (ja) | 2023-09-25 |
| JP2021519783A (ja) | 2021-08-12 |
| EA202092320A1 (ru) | 2021-03-09 |
| US20210115045A1 (en) | 2021-04-22 |
| MA52232A (fr) | 2021-02-17 |
| TW201946629A (zh) | 2019-12-16 |
| MX2020010005A (es) | 2020-10-14 |
| KR20200138769A (ko) | 2020-12-10 |
| AU2019243289A1 (en) | 2020-09-24 |
| CN111936499A (zh) | 2020-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277665A (en) | Heterocyclic inhibitors of MAT2A and methods of use for cancer therapy | |
| IL288395A (en) | Mat2a tricyclic inhibitors and methods for use in cancer therapy | |
| IL284324A (en) | Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer | |
| IL284326A (en) | Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer | |
| IL272948B1 (en) | enpp1 inhibitors and their use for cancer treatment | |
| IL273824A (en) | Methods of using ehmt2 inhibitors in the treatment or prevention of blood disorders | |
| SG11202001282UA (en) | Shp2 inhibitor compositions and methods for treating cancer | |
| IL267455A (en) | Phosphodiesterase inhibitors and methods of treating bacteria | |
| EP3464643A4 (en) | USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER | |
| EP3890749A4 (en) | CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS CANCER TREATMENT AGENT | |
| IL254842A0 (en) | Therapeutic preparations and methods for use in cancer treatment | |
| IL266182A (en) | Farensyltransferase inhibitors for use in cancer treatment methods | |
| HK1244436A1 (zh) | 治療癌症的hsp90抑制劑和pd-1抑制劑的組合療法 | |
| IL274198A (en) | Use of Nox inhibitors to treat cancer | |
| EP3576766A4 (en) | CYCLIN-G1 INHIBITORS AND RELATED METHODS FOR TREATING CANCER | |
| IL277918A (en) | A combination of LIF inhibitors and PD-1 AXIS inhibitors for use in cancer therapy | |
| EP3630080A4 (en) | USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER | |
| IL276203A (en) | Compounds and methods for treating cancer | |
| IL291424A (en) | Use of dkk-1 inhibitors to treat cancer | |
| EP3758678A4 (en) | CANCER TREATMENT METHODS INCLUDING CHK1 INHIBITORS | |
| EP3856352A4 (en) | Methods of treatment of cancer comprising cdc7 inhibitors | |
| IL288003A (en) | Cancer treatment methods using chk1 inhibitors | |
| GB201709417D0 (en) | Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer | |
| IL282738A (en) | Methods of treating cancer with farnesyltransferase inhibitors | |
| GB201709076D0 (en) | Parp inhibitors for use in methods of treating cancer |